Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.34 |
| ▸ | ADK | P55263 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038377 | 0.77 | ALDH1A1 (0.62) | ALDH1A1HTTNT5EP2RY6LMNA | |
| SCHEMBL29455714 | 0.76 | AHCY (0.49) | ALDH1A1HTTLMNATHRBMTOR | |
| SCHEMBL23098378 | 0.74 | ADK (0.56) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11790069 | 0.73 | ALDH1A1 (0.47) | ALDH1A1HTTP2RY6LMNATHRB | |
| SCHEMBL15111406 | 0.73 | ADK (0.39) | ALDH1A1HTTLMNATHRBMTOR | |
| SCHEMBL15855041 | 0.73 | NT5E (0.40) | NT5EP2RY6ADK | |
| SCHEMBL5888586 | 0.73 | AHCY (0.61) | PRMT5WDR77 | |
| SCHEMBL21275623 | 0.72 | LMNA (0.50) | ALDH1A1HTTLMNATHRBMTOR | |
| SCHEMBL16629487 | 0.72 | LMNA (0.50) | ALDH1A1HTTLMNATHRBMTOR | |
| Diphenylether SCHEMBL3231397 | 0.71 | ADORA2A (0.55) | ALDH1A1HTTP2RY6LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030230-B2 | Process of purifying phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | claimed |
| WO-2004039469-A2 | PROCESS OF PURIFYING PHOSPHORAMIDITES | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040082775-A1 | Process of purifying phosphoramidites | ISIS PHARMACEUTICALS INC. | 2004-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082775-A1 | Process of purifying phosphoramidites | PHOSPHO1, ADAR, POLRMT | ALDH1A1 4728/4885HTT 1325/4885NT5E 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.